NTP-METHYLPHENIDATE ER-C TABLET (EXTENDED-RELEASE)

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

METHYLPHENIDATE HYDROCHLORIDE

可用日期:

NT PHARMA CANADA LTD

ATC代码:

N06BA04

INN（国际名称）:

METHYLPHENIDATE

剂量:

18MG

药物剂型:

TABLET (EXTENDED-RELEASE)

组成:

METHYLPHENIDATE HYDROCHLORIDE 18MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Schedule G (CDSA III)

治疗领域:

Respiratory and CNS Stimulants

產品總結:

Active ingredient group (AIG) number: 0107548004; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2017-08-21

产品特点

_ _
PRODUCT MONOGRAPH
NTP-METHYLPHENIDATE ER-C
(Methylphenidate Hydrochloride)
Extended-release Tablets 18 mg, 27 mg, 36 mg, and 54 mg
NT Pharma Standard
CNS Stimulant
NT Pharma Canada Limited
Date of Preparation:
5691 Main Street
March 18, 2010
Stouffville, Ontario
Canada, L4A 1H5
Submission Control No: 136744
C
_Page 2 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND
PRECAUTIONS.........................................................................................
5
ADVERSE
REACTIONS...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
15
DOSAGE AND
ADMINISTRATION.....................................................................................
16
OVERDOSAGE
.......................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 19
STORAGE AND
STABILITY.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 24
PART II: SCIENTIFIC
INFORMATION....................................................................................
25
PHARMACEUTICAL
INFORMATION.................................................................................
25
CLINICAL
TRIALS..............................................................